Equities analysts expect that Lannett Company, Inc. (NYSE:LCI) will post sales of $176.30 million for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Lannett’s earnings. The lowest sales estimate is $172.60 million and the highest is $182.14 million. Lannett reported sales of $165.72 million in the same quarter last year, which would suggest a positive year over year growth rate of 6.4%. The firm is expected to announce its next earnings results on Tuesday, May 1st.
According to Zacks, analysts expect that Lannett will report full-year sales of $176.30 million for the current year, with estimates ranging from $681.80 million to $714.17 million. For the next fiscal year, analysts expect that the business will report sales of $686.96 million per share, with estimates ranging from $653.68 million to $742.74 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover Lannett.
Lannett (NYSE:LCI) last released its quarterly earnings data on Wednesday, February 7th. The company reported $1.06 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.86 by $0.20. Lannett had a net margin of 7.44% and a return on equity of 18.85%. The business had revenue of $184.31 million during the quarter, compared to analyst estimates of $190.92 million. During the same quarter last year, the business earned $0.92 earnings per share. Lannett’s quarterly revenue was up 7.8% compared to the same quarter last year.
LCI stock traded down $0.05 during trading on Friday, hitting $16.20. 400,524 shares of the company’s stock traded hands, compared to its average volume of 715,430. Lannett has a 52 week low of $14.40 and a 52 week high of $30.35. The company has a quick ratio of 1.77, a current ratio of 2.32 and a debt-to-equity ratio of 1.38. The firm has a market capitalization of $577.11, a P/E ratio of 5.61, a price-to-earnings-growth ratio of 0.97 and a beta of 2.50.
Institutional investors have recently added to or reduced their stakes in the company. Neuberger Berman Group LLC bought a new stake in shares of Lannett in the 3rd quarter worth about $188,000. Municipal Employees Retirement System of Michigan lifted its holdings in shares of Lannett by 59.1% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 11,040 shares of the company’s stock worth $204,000 after acquiring an additional 4,100 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in shares of Lannett in the 4th quarter worth about $223,000. Unison Advisors LLC bought a new stake in shares of Lannett in the 4th quarter worth about $273,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in shares of Lannett by 66.6% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 15,384 shares of the company’s stock worth $284,000 after acquiring an additional 6,149 shares during the last quarter. Hedge funds and other institutional investors own 98.40% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “$176.30 Million in Sales Expected for Lannett Company, Inc. (LCI) This Quarter” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://weekherald.com/2018/04/18/176-30-million-in-sales-expected-for-lannett-company-inc-lci-this-quarter.html.
Lannett Company Profile
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.